Design of a Closed-loop Controller Based on the Bispectral Index (BIS) Effectiveness of the Smith Predictor

March 3, 2017 updated by: José Antonio Reboso Morales

Design of a Closed-loop Controller for the Administration of Propofol Based on the Bispectral Index (BIS). Effectiveness of the Smith Predictor and Comparison With Manual Control

The action of anesthetics such as propofol is not immediate after intravenous administration. Delay in pharmacodynamic effect of intravenous drugs is a commonly observed phenomenon in total intravenous anesthesia (TIVA). On the other hand, the measure of the clinical effect of propofol by EEG processed monitors like the bispectral index (BIS) also requires some processing time for the analysis of the recorded signal. Thus, the resulting BIS value provided by the monitor is affected by a delay. When a BIS based controller is used, the propofol infusion rates are defined using information of the BIS signal available. The delay in the BIS signal is an important issue as it can affect the performance of the controller. There are scarce contributions to address the delay in automatic administration of anesthesia.

Our proposal to deal with the dead time in the control action of the hypnotic component of anesthesia is a proportional-integral (PI) algorithm with a Smith predictor. The aim of this study is to evaluate and compare the feasibility and effectiveness of a closed-loop control using the Smith predictor versus manual control for propofol administration guided by the bispectral index (BIS) in adults patients. The objective is to show that a closed loop control can be a useful tool to provide safe and effective intravenous anesthesia and that the use of specific controller for delay rejection is a reliable strategy.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Unknown

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Modern medicine is focused on individualized treatment, including a personalized anesthesia administration. This implies to maintain the patient hypnotic state as closer as possible to a set target. TIVA with propofol and remifentanil has increased in popularity in recent years. Automatic systems can free the anesthesiologist of repetitive tasks. So, closed loop administration has been proposed to adjust propofol infusion rate without anesthesiologist intervention apart from supervising the procedure. A desired target of BIS is chosen by the clinician and feedback from the BIS monitor is used to adjust the rate of drug delivery continuously.

Closed loop control offers the opportunity of adjust the administration of anesthetics in an individualized way. It is also expected to overcome the individual pharmacokinetic and pharmacodynamic variability and to show a better adaptation to different levels of surgical stimulation. Closed loop control of propofol administration provides a greater stability in the level of hypnosis with a lower total dose of drug administered. Therefore, the recovery after anesthesia can be shorter. This can promote a better quality anesthetic care.

Previous studies with a PI controller showed in some patients a tendency to oscillate around a target value. This can be originated by the delay present in the system. One of the most known strategies in engineering to face the delay in closed loop is the Smith predictor. The purpose of this study is to evaluate and compare the feasibility and efficacy of a closed-loop control with a PI plus a Smith predictor algorithm versus manual control for propofol administration guided by the bispectral index (BIS) in adults patients.

Two groups of 25 adult patients scheduled for gynecological, urologic or abdominal surgery with an estimated duration > 30 minutes will be enrolled and randomized to one of the 2 groups. In the Manual control group (MC), the propofol infusion rate will be adjusted at the discretion of the anesthesiologist. In the PI+Smith group, propofol will be administered automatically by the closed-loop anesthesia system. The controller calculated automatically the error (target BIS - actual BIS) every 5 s and governed the infusion pump adapting the rate of propofol. The goal in both groups is to maintain BIS between 40 and 60 during maintenance phase of anesthesia. This is the recommended range of BIS for an adequate level of hypnosis during general anesthesia. Remifentanil will be infused for analgesia with the objective of to avoid an inadequate level of analgesia that could affect the stability of BIS signal.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Anticipated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
50

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
    • Santa Cruz de Tenerife
      • La Laguna, Santa Cruz de Tenerife, Spain, 38320
        • Hospital Universitario de Canarias

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Ability to provide informed consent
  • 18 years of age or older
  • Classification of the American Society of Anesthesiologists (ASA) as I or II
  • Elective surgical procedures requiring general anesthesia with an estimated duration > 30 minutes

Exclusion Criteria:

  • Pregnant women,
  • Patients with neurological or psychiatric disorders
  • Patients taking any medication known to influence the EEG and subsequently the BIS

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: 1: Manual control group
The propofol infusion rate is adjusted manually in a pump by the investigator to maintain BIS between 40 and 60. For this titration it is necessary continuous monitoring, clinical experience, and pharmacokinetic/pharmacodynamic knowledge.
Drug: Propofol
Closed loop control for propofol administration guided by the BIS.
Drug: Propofol
Manual control group: Propofol administration adjusted manually.
Experimental: 2: PI +Smith group
The closed loop control automatically adjust propofol infusion rate guided by the feedback of the real value of BIS. The automatic system has to achieve a target BIS of 50 and maintain it between 40 and 60.
Drug: Propofol
Closed loop control for propofol administration guided by the BIS.
Drug: Propofol
Manual control group: Propofol administration adjusted manually.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Evaluation of the performance of the 2 groups with the global score (GS).
Time Frame: During anesthesia maintenance, approximately 9 hours

Global score is a calculated parameter which gives an idea of the overall performance of a closed-loop system. It is calculated as the sum of MDAPE and wobble divided by the fraction of time BIS was within ±10 of the target. The target BIS chosen will be 50. The GS is calculated according the formula:

GS = (MDAPE + wobble)/ % of time with BIS between 40 and 60
During anesthesia maintenance, approximately 9 hours

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
The percentage of time with BIS values within +/10 % of target BIS.
Time Frame: During anesthesia maintenance, approximately 9 hours
Adequate depth of anaesthesia during surgical interventions
During anesthesia maintenance, approximately 9 hours
MDPE (median performance error)
Time Frame: During anesthesia maintenance, approximately 9 hours
The difference between the observed and target value of BIS.
During anesthesia maintenance, approximately 9 hours
MDAPE (median absolute performance error):
Time Frame: During anesthesia maintenance, approximately 9 hours
The median of the absolute values of performance errors.
During anesthesia maintenance, approximately 9 hours
Wobble
Time Frame: During anesthesia maintenance, approximately 9 hours
The median of the difference between individual PE and the MDPE for each participant, it measures the intra-individual variability of PE.
During anesthesia maintenance, approximately 9 hours
Time to eyes opening
Time Frame: 30 minutes after the end of the anesthesia
Time from discontinuation of the propofol and remifentanil infusions until the patient is able to open his eyes on command.
30 minutes after the end of the anesthesia
Time to tracheal extubation:
Time Frame: 30 minutes after the end of the anesthesia
Time from discontinuation of propofol infusion until endotracheal tube removal.
30 minutes after the end of the anesthesia
Total consumption of propofol and remifentanil during anesthesia maintenance
Time Frame: During anesthesia maintenance, approximately 9 hours
Propofol administered
During anesthesia maintenance, approximately 9 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
José Antonio Reboso Morales

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
University of La Laguna

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 6, 2017

Primary Completion (Anticipated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 15, 2017

Study Completion (Anticipated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 15, 2017

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 24, 2017

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 3, 2017

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 8, 2017

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 8, 2017

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 3, 2017

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2017_

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on General Anesthesia

Clinical Trials on Propofol

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings